SOURCE: Biotie Therapies Oyj

September 04, 2009 04:00 ET

Biotie Therapies to present at Rodman & Renshaw Annual Healthcare Conference

TURKU, FINLAND--(Marketwire - September 4, 2009) -

BIOTIE THERAPIES CORP. Press Release September 4, 2009 at 11 a.m.

Biotie Therapies to present at Rodman & Renshaw Annual Healthcare Conference

Rodman & Rodman Annual Global Investment Conference 2009

Live webcast will be available at

Biotie Therapies Corp. (NASDAQ OMX: BTH1V) announced today that Dr. Timo Veromaa, President and Chief Executive Officer, will give an update on the company at the Rodman & Renshaw 11th Annual Healthcare Conference in New York on Wednesday September 9, 2009 at 10:50 a.m. local time (5:50 p.m. Finnish time).

For more information on the conference:

The audio and slide presentation will be webcasted live and will be available for 90 days at

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail:

About Biotie Therapies Corp.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie's products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland and Radebeul, Germany. Shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information